Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Guggenheim 

BeiGene Ltd ADR diskutieren

BeiGene Ltd ADR

WKN: A1437N / Symbol: BGNE / Name: BeiGene / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

151,00 €
3,45 %

Einschätzung Buy
Rendite (%) -26,17 %
Kursziel 329,84
Veränderung
Endet am 28.02.24

BeiGene, Ltd. (NASDAQ: BGNE) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $350.00 price target on the stock.
Ratings data for BGNE provided by MarketBeat

Einschätzung Buy
Rendite (%) -13,87 %
Kursziel 272,64
Veränderung
Endet am 07.08.24

BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at JPMorgan Chase & Co. from $297.00 to $300.00. They now have an "overweight" rating on the stock.
Ratings data for BGNE provided by MarketBeat

Einschätzung Buy
Rendite (%) -24,75 %
Kursziel 295,36
Veränderung
Endet am 29.08.24

BeiGene, Ltd. (NASDAQ: BGNE) had its price target lowered by analysts at Morgan Stanley from $321.00 to $319.00. They now have an "overweight" rating on the stock.
Ratings data for BGNE provided by MarketBeat

Einschätzung Buy
Rendite (%) -21,99 %
Kursziel 241,54
Veränderung
Endet am 12.09.24

BeiGene, Ltd. (NASDAQ: BGNE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $259.00 price target on the stock.
Ratings data for BGNE provided by MarketBeat

Einschätzung Buy
Rendite (%) -7,93 %
Kursziel 270,24
Veränderung
Endet am 26.10.24

BeiGene, Ltd. (NASDAQ: BGNE) had its price target lowered by analysts at Citigroup Inc. from $290.00 to $285.00. They now have a "buy" rating on the stock.
Ratings data for BGNE provided by MarketBeat

BeiGene, Ltd. (NASDAQ: BGNE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for BGNE provided by MarketBeat

Einschätzung Buy
Rendite (%) 9,42 %
Kursziel 172,29
Veränderung
Endet am 06.02.25

BeiGene, Ltd. (NASDAQ: BGNE) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $185.00 price target on the stock.
Ratings data for BGNE provided by MarketBeat

Einschätzung Buy
Rendite (%) -9,04 %
Kursziel 317,85
Veränderung
Endet am 27.02.25

BeiGene, Ltd. (NASDAQ: BGNE) had its price target lowered by analysts at Guggenheim from $350.00 to $345.00. They now have a "buy" rating on the stock.
Ratings data for BGNE provided by MarketBeat

Einschätzung Buy
Rendite (%) -2,58 %
Kursziel 171,40
Veränderung
Endet am 20.03.25

BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at JPMorgan Chase & Co. from $184.00 to $186.00. They now have an "overweight" rating on the stock.
Ratings data for BGNE provided by MarketBeat

Einschätzung Buy
Rendite (%) 8,03 %
Kursziel 220,61
Veränderung
Endet am 24.04.25

BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $235.00 to $236.00. They now have a "buy" rating on the stock.
Ratings data for BGNE provided by MarketBeat